Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L-tryptophan recall

Executive Summary

FDA expanding its recall of the dietary supplement to include products that contain any dosage of the amino acid, the agency announced in a March 22 release. Products not subject to the recall are "some protein supplements, infant formulas, special dietary foods, and I.V. and oral solutions in which small amounts of L-tryptophan are needed for nutrient fortification." FDA said that reports of eosinophilia-myalgia syndrome (EMS) linked to L-tryptophan products "have climbed to 1,411, with 19 deaths." The initial recall, which began Nov. 17, involved products that would result in a daily intake of 100 mg or more of L-tryptophan. At the time, 287 illnesses and four deaths were reported.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel